Catrin Sohrabi, Bunny Saberwal, Wei-Yao Lim, Dimitris Tousoulis, Syed Ahsan and Nikolaos Papageorgiou* Pages 5933 - 5952 ( 20 )
Diabetes mellitus (DM) and heart failure (HF) are comorbid conditions associated with significant morbidity and mortality worldwide. Despite the availability of novel and effective therapeutic options and intensive glycaemic control strategies, mortality and hospitalisation rates continue to remain high and the incidence of HF persists. In this review, we described the impact of currently available glucose-lowering therapies in DM with a focus on HF clinical outcomes. Non-conventional modes of management and alternative pathophysiological mechanisms with the potential for therapeutic targeting are also discussed.
Heart failure, diabetes, T2DM, diabetic cardiomyopathy, HF, DM.
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, Electrophysiology Department, Barts Heart Centre, St. Bartholomew’s Hospital, West Smithfield, London, Electrophysiology Department, Barts Heart Centre, St. Bartholomew’s Hospital, West Smithfield, London, First Cardiology Department, Hippokration Hospital, Athens University Medical School, Athens, Electrophysiology Department, Barts Heart Centre, St. Bartholomew’s Hospital, West Smithfield, London, Electrophysiology Department, Barts Heart Centre, St. Bartholomew’s Hospital, West Smithfield, London